Holen Sie sich die Stockscreener-App
1.415
2.54%
0.035
Medicinova Inc Aktie (MNOV) Neueste Nachrichten
Quarterly Recap: What is the next catalyst for MediciNova IncChart Signals & Fast Moving Trade Plans - baoquankhu1.vn
Trend Review: Is MediciNova Inc a stock for growth or value investorsWeekly Trading Summary & AI Forecasted Stock Moves - baoquankhu1.vn
MediciNova (NASDAQ:MNOV) Stock Passes Above 200-Day Moving AverageShould You Sell? - MarketBeat
Can MediciNova Inc continue delivering strong returnsMarket Activity Recap & Weekly Setup with ROI Potential - baoquankhu1.vn
Aug Analyst Calls: Can AACG be recession proofJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MediciNova (MNOV) Price Target Increased by 11.11% to 10.20 - Nasdaq
Breakout Watch: What analysts say about MediciNova Inc stockGDP Growth & Daily Growth Stock Investment Tips - baoquankhu1.vn
Market Moves: Can MediciNova Inc continue delivering strong returns2025 Stock Rankings & Risk Managed Trade Strategies - baoquankhu1.vn
MediciNova: Q4 Earnings Snapshot - Stamford Advocate
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MediciNova (NASDAQ:MNOV) Posts Quarterly Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
Aug PreEarnings: What analysts say about MediciNova Inc stockJuly 2025 Setups & Daily Profit Focused Stock Screening - baoquankhu1.vn
Can MediciNova Inc. continue delivering strong returnsJuly 2025 EndofMonth & Long-Term Safe Return Strategies - mfd.ru
MediciNova reports preliminary 2025 financial results in Tokyo filing By Investing.com - Investing.com India
MediciNova Financial Report: Q4 & Annual 2025 ResultsLoss & Revenue FiguresNews and Statistics - IndexBox
MediciNova reports preliminary 2025 financial results in Tokyo filing - Investing.com
4875.T MediciNova (JPX) JPY 254.00 pre-earnings 19 Feb: catalysts to watch - Meyka
MediciNova, Inc. (NASDAQ:MNOV) Short Interest Update - MarketBeat
MediciNova (MNOV) Projected to Post Earnings on Wednesday - MarketBeat
Does MediciNova Inc. have strong fundamentalsRisk Management & Fast Exit and Entry Trade Guides - mfd.ru
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving AverageHere's What Happened - MarketBeat
MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average – Here’s What Happened - Defense World
RSI Check: Is MediciNova Inc a stock for growth or value investorsQuarterly Portfolio Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Performance Recap: Is MediciNova Inc backed by strong institutional buyingLong Setup & Daily Profit Maximizing Tips - baoquankhu1.vn
MediciNova (MNOV) Price Target Increased by 28.57% to 9.18 - Nasdaq
Drug Developer Uncovers Excellent Progress in 200-Patient ALS Study - streetwisereports.com
Trading Action: Is MediciNova Inc. a stock for growth or value investorsBond Market & Verified Momentum Stock Ideas - baoquankhu1.vn
Biopharma Reaches 50% Enrollment in New ALS Drug Program - streetwisereports.com
MediciNova, Inc. (NASDAQ:MNOV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
D. Boral Capital Reaffirms “Buy” Rating for MediciNova (NASDAQ:MNOV) - Defense World
MediciNova's (MNOV) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
MediciNova reaches 50% enrollment milestone in ALS drug study By Investing.com - Investing.com Nigeria
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients - The Manila Times
MediciNova reaches 50% enrollment milestone in ALS drug study - Investing.com
ALS patients gain wider access as MediciNova trial reaches 100 enrollees - stocktitan.net
MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving AverageWhat's Next? - MarketBeat
Institution Moves: What are the risks of holding Real Messenger CorporationTrade Ideas & Consistent Return Investment Signals - baoquankhu1.vn
MNOVMediciNova Reports Third Quarter 2011 Results - ADVFN
Dip Buying: Can MediciNova Inc continue delivering strong returnsTrade Signal Summary & Short-Term High Return Ideas - baoquankhu1.vn
MediciNova Announces Additional Analyses from Completed Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 30th Int... - ADVFN
MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving AverageShould You Sell? - MarketBeat
MediciNova (NASDAQ:MNOV) Share Price Crosses Above 200 Day Moving Average – Should You Sell? - Defense World
Price Action: How sensitive is MediciNova Inc to inflationMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Aug Patterns: Why MediciNova Inc. stock could benefit from AI revolutionMarket Growth Summary & Long-Term Capital Growth Strategies - Bộ Nội Vụ
Rate Hike: Why MediciNova Inc. stock could benefit from AI revolution2025 Trading Recap & Accurate Buy Signal Alerts - Bộ Nội Vụ
Columbia University/New York State Psychiatric Institute and MediciNova Report Preliminary Safety and Efficacy of Ibudilast in H - ADVFN
MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver - ADVFN
FDA Grants Fast Track Designation for MediciNova's MN-166 (ibudilast) for the Treatment of Methamphetamine Dependence - ADVFN
Insider Buy: Will MediciNova Inc stock outperform value stocksJuly 2025 Action & Low Volatility Stock Recommendations - moha.gov.vn
Why MediciNova Inc. stock could benefit from AI revolutionMarket Trend Report & Expert Approved Momentum Trade Ideas - Улправда
Will MediciNova Inc. stock beat EPS estimatesPortfolio Gains Summary & Weekly High Conviction Trade Ideas - Улправда
MediciNova Receives a Notice of Allowance for a Method of Treating Drug Addiction or Dependence - ADVFN
Whale Trades: Why MediciNova Inc. stock could benefit from AI revolutionBear Alert & AI Driven Price Forecasts - Улправда
Is MediciNova Inc. stock a good choice for value investors2025 Support & Resistance & Precise Swing Trade Alerts - Улправда
1.30%
20.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):